This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
American Cancer Society. ‘Cancer facts, figures2013.http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf Accessed’ November 30, 2014.American Cancer Society‘Cancer factsfigures2013http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdfAccessed’November302014Search in Google Scholar
DeSantis CE, Lin CC, Mariotto AB, et al. ‘Cancer treatment and survivorship statistics’, 2014. CA Cancer J Clin. 2014;64:252–271.DeSantisCELinCCMariottoAB‘Cancer treatment and survivorship statistics’2014CA Cancer J Clin20146425227110.3322/caac.2123524890451Search in Google Scholar
Haugen BR, Alexander EK, Bible KC et al. ‘American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.’ Thyroid. 2016; 26(1):1–133.2646296710.1089/thy.2015.0020HaugenBRAlexanderEKBibleKC‘American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.’Thyroid20162611133473913226462967Search in Google Scholar
Davies L, Welch HG. ‘Thyroid cancer survival in the United States: observational data from 1973 to 2005’. Arch Otolaryngology Head Neck Surg. 2010;136:440–444.10.1001/archoto.2010.55DaviesLWelchHG.‘Thyroid cancer survival in the United States: observational data from 1973 to 2005’Arch Otolaryngology Head Neck Surg201013644044420479371Open DOISearch in Google Scholar
Jonklaas J, Sarlis NJ, Litofsky D, et al. ‘Outcomes of patients with differentiated thyroid carcinoma following initial therapy’. Thyroid. 2006;16:1229– 1242.10.1089/thy.2006.16.1229JonklaasJSarlisNJLitofskyD‘Outcomes of patients with differentiated thyroid carcinoma following initial therapy’Thyroid2006161229124217199433Open DOISearch in Google Scholar
Morris LF, Romero Arenas MA, et al. ‘Streamlining variability in hospital charges for standard thyroidectomy: developing a strategy to decrease waste.’ Surgery. 2014;156:1441–1449.10.1016/j.surg.2014.08.06825456929MorrisLFRomero ArenasMA‘Streamlining variability in hospital charges for standard thyroidectomy: developing a strategy to decrease waste.’Surgery20141561441144925456929Open DOISearch in Google Scholar
Castagna, M. G., S. Cantara, and F. Pacini. ‘Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients: Journal of Endocrinological Investigation.’ 2016; 39:1087–1094.CastagnaM. G.CantaraS.andF.Pacini‘Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients: Journal of Endocrinological Investigation.’20163910871094Search in Google Scholar
Mendoza A, Shaffer B, Karakla D, et al. ‘Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction.’ Thyroid. 2004;14:133–140.[PubMed]10.1089/10507250432288037315068628MendozaAShafferBKaraklaD‘Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction.’Thyroid200414133140[PubMed]15068628Open DOISearch in Google Scholar
Almeida JP, Sanabria AE, Lima EN, et al.. ‘Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer.’ Head Neck. 2011;33:686–690.[PubMed]2148491710.1002/hed.21520AlmeidaJPSanabriaAELimaEN‘Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer.’Head Neck201133686690[PubMed]21484917Search in Google Scholar
Sawka AM, Thabane L, Parlea L, et al. ‘Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.’ Thyroid. 2009;19:451–457. [PubMed]10.1089/thy.2008.039219281429SawkaAMThabaneLParleaL‘Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.’Thyroid200919451457[PubMed]19281429Open DOISearch in Google Scholar
Iyer NG, Morris LG, Tuttle RM, et al. ‘Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.’ Cancer. 2011;117:4439–4446.[PMC free article][PubMed]2143284310.1002/cncr.26070IyerNGMorrisLGTuttleRM‘Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.’Cancer201111744394446[PMC free article][PubMed]315586121432843Search in Google Scholar
Podnos YD, Smith DD, Wagman LD, et al. ‘Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope’ .J Surg Oncol. 2007;96:3–7.[PubMed]10.1002/jso.20656PodnosYDSmithDDWagmanLD‘Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope’J Surg Oncol20079637[PubMed]17567872Open DOISearch in Google Scholar
Jonklaas J, Sarlis NJ, Litofsky D, et al. ‘Outcomes of patients with differentiated thyroid carcinoma following initial therapy.’ Thyroid. 2006;16:1229– 1242.[PubMed]1719943310.1089/thy.2006.16.1229JonklaasJSarlisNJLitofskyD‘Outcomes of patients with differentiated thyroid carcinoma following initial therapy.’ Thyroid20061612291242[PubMed]17199433Search in Google Scholar
Hay ID, Thompson GB, Grant CS, et al. ‘Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.’ .World J Surg. 2002;26:879–885.[PubMed]10.1007/s00268-002-6612-1HayIDThompsonGBGrantCS‘Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.’World J Surg200226879885[PubMed]12016468Open DOISearch in Google Scholar
Ewa Ruel, Samantha Thomas, Michaela Dinan, et al. ‘Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer.’ J ClinEndocrinolMetab. 2015 Apr; 100(4): 1529– 1536.EwaRuelSamanthaThomasMichaelaDinan‘Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer.’J ClinEndocrinolMetab.2015Apr10041529153610.1210/jc.2014-4332439928225642591Search in Google Scholar
M. G. Castagna1, S. Cantara, F. Pacini. ‘Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.’ J Endocrinol Invest (2016) 39:1087–10942735055610.1007/s40618-016-0503-zCastagna1M. G.CantaraS.PaciniF.‘Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.’J Endocrinol Invest2016391087109427350556Search in Google Scholar
Adam MA, Pura J, Goffredo P et al . ‘Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer.’ J ClinOncol. 2015;33:2370–237510.1200/JCO.2014.59.8391AdamMAPuraJGoffredoP‘Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer.’J ClinOncol.2015332370237526077238Open DOISearch in Google Scholar
Randolph GW, Duh QY, Heller KS et al. ‘The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.’ Thyroid.2012 22:1144–115210.1089/thy.2012.004323083442RandolphGWDuhQYHellerKS‘The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.’Thyroid.2012221144115223083442Open DOISearch in Google Scholar
